Deputy Secretary of Agency Integration and State Medicaid Director
Key decision makers in the same organization
Organization Signals
Public Activity & Signals
Board meetings, strategic plans, and buyer signals from Pamela McKinsey’s organization
May 20, 2026·BoardMeeting
Board
Drug Utilization Review Board Meeting Agenda
The board meeting agenda focuses on the review of several pharmaceutical-related items, including revisions to prior authorization criteria for various medication categories such as immune globulins, oncology agents, epidermolysis bullosa treatments, and high-cost dosage forms. The meeting also involves establishing new prior authorization criteria for agents addressing cholestatic pruritus, chronic hand eczema, hereditary angioedema, macular telangiectasia, non-factor hemophilia prophylaxis, and Prader-Willi syndrome. Additionally, the agenda includes discussions on safe usage guidelines for ADHD and antipsychotic medications, as well as utilization data for T-cell receptor immunotherapy agents.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
Mental Health Medication Advisory Committee Meeting Minutes Open Session
The committee discussed and approved updates to medication criteria, including the addition of Arynta for ADHD and changes to step therapy for several antipsychotic medications such as Caplyta, Fanapt, Rexulti, and Vraylar. The committee requested state data regarding the cost-impact of step therapy and requested that haloperidol be included as an option for step therapy. Additionally, the committee asked for data updates concerning polypharmacy prescribing in children and information on whether existing policies have successfully reduced prescriber burden.
Jan 21, 2026·BoardMeeting
Board
Drug Utilization Review Board Meeting Agenda
The meeting agenda focuses on reviewing pharmaceutical criteria and utilization data. Key topics include proposed changes to prior authorization criteria for various drug categories, including oncology agents, Duchenne Muscular Dystrophy gene therapy, generalized Myasthenia Gravis agents, and metabolic dysfunction-associated steatohepatitis treatments. Additionally, the board will discuss new criteria for Hemophilia prophylaxis and Prader-Willi Syndrome agents, as well as review utilization data for T-cell receptor immunotherapy. Tentative agenda items from previous MHMAC and PDL meetings concerning ADHD, antidepressants, and postpartum depression medications are also slated for review.
Jan 20, 2026·BoardMeeting
Board
Preferred Drug List Committee Meeting Agenda
The committee meeting agenda covers the review of new drug placements on the Preferred Drug List, including various medications for pain management, hypertension, and diabetes. New business includes discussions and committee recommendations for new Preferred Drug List classes, such as agents for Familial Chylomicronemia Syndrome, Non-Factor Hemophilia A and B Prophylaxis, and Sickle Cell Anemia treatments. Additionally, the agenda addresses new drugs to be added to existing classes for conditions like Dry Eye Disease, Atopic Dermatitis, Migraine treatments, Thrombopoiesis Stimulating Proteins, and nonhormonal therapies for Vasomotor Symptoms, with opportunities for public comment for each item.
Extracted from official board minutes, strategic plans, and video transcripts.
